RecruitingPhase I/IIEN originalLiver cancerMetastatic / advanced

Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatment in Adult Participants With a Liver Cancer Called Hepatocellular Carcinoma, That is Too Advanced to be Removed by Surgery and May Have Spread to Other Parts of the Body.

⚠️

This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.

About the trial

The purpose of this study is to learn about the effects of study medicine (PF-08634404) when given alone or with another antibody (ipilimumab) for the treatment of a type of liver cancer called hepatocellular carcinoma (HCC) that is either locally advanced (spread to nearby tissues) or has spread to other parts of the body. To join the study, participants must meet the following conditions: * Be 18 years or older. * Have locally advanced or metastatic HCC. * Is not a candidate for complete surgical or loco-regional therapies. * Have not received any whole-body treatment for HCC. Participants will receive PF-08634404 either alone or in combination with ipilimumab. The medicine will be given through intravenous (IV) infusions, which means it will be administered directly into a vein. All treatments will take place at clinical trial sites, where trained medical staff will monitor participants during and after each visit.

Original English text from ClinicalTrials.gov

Who can (and can't) join

✓ Qualifies

  • Masz co najmniej 18 lat.
  • Masz zaawansowanego raka wątroby, który rozprzestrzenił się na inne części ciała lub sąsiednie tkanki.
  • Nie możesz być operowany lub poddany innym miejscowym leczeniom.
  • Nie otrzymałeś wcześniej żadnego ogólnoustrojowego leczenia raka wątroby.
  • Masz co najmniej jedną zmianę chorobową, którą można zmierzyć.
  • Twoje narządy (wątroba, nerki) działają wystarczająco dobrze.

✗ Disqualifies

  • Masz wodobrzusze (nadmiar płynu w jamie brzusznej) o umiarkowanym lub ciężkim nasileniu.
  • Miałeś w przeszłości encefalopatię wątrobową (zaburzenia mózgu związane z chorobą wątroby).
  • Masz aktywne przerzuty do mózgu lub rdzenia kręgowego.
  • Masz znaczące ryzyko krwawienia lub powstawania przetok (nienormalnych połączeń między narządami).
  • Chorowałeś na innego raka w ciągu ostatnich 3 lat.
  • Miałeś przeszczep narządu lub komórek macierzystych.
  • Masz aktywne choroby autoimmunologiczne wymagające leczenia w ciągu ostatnich 2 lat.
  • Miałeś poważne problemy z sercem lub naczyniami krwionośnymi w ciągu ostatnich 6 miesięcy.

Simplified criteria — AI translation

Trial details

Minimum age
18 Years
Last updated (source)
July 22, 2026
Sex
No restrictions

Therapies / drugs in trial

Locations (49)

Keck Hospital of USC

Los Angeles, United States

Los Angeles General Medical Center

Los Angeles, United States

USC/Norris Comprehensive Cancer Center / Investigational Drug Services

Los Angeles, United States

USC/Norris Comprehensive Cancer Center

Los Angeles, United States

Keck Medical Center of USC Pasadena

Pasadena, United States

Moffitt Cancer Center at Speros

Land O' Lakes, United States

Moffitt Cancer Center at SouthShore

Ruskin, United States

Moffitt Cancer Center - International Plaza

Tampa, United States

Moffitt Cancer Center - McKinley Campus

Tampa, United States

Moffitt Cancer Center

Tampa, United States

Moffitt McKinley Hospital

Tampa, United States

Moffitt Cancer Center at Wesley Chapel

Wesley Chapel, United States

Memorial Hospital

Shiloh, United States

Siteman Cancer Center - Shiloh

Shiloh, United States

Allina Health Cancer Institute - Mercy Hospital

Coon Rapids, United States

Allina Health Cancer Institute - Abbott Northwestern Hospital

Minneapolis, United States

Allina Health Cancer Institute - United Hospital

Saint Paul, United States

Siteman Cancer Center - St. Peters

City of Saint Peters, United States

Siteman Cancer Center - West County

Creve Coeur, United States

Siteman Cancer Center - North County

Florissant, United States

Saint Luke's Cancer Institute

Kansas City, United States

Saint Luke's Hospital of Kansas City

Kansas City, United States

Siteman Cancer Center

St Louis, United States

Barnes-Jewish Hospital

St Louis, United States

Washington University School of Medicine - Siteman Cancer Center

St Louis, United States

Siteman Cancer Center - South County

St Louis, United States

Renown Health Medical Oncology

Reno, United States

Renown Office of Clinical Research

Reno, United States

Renown Regional Medical Center

Reno, United States

Duke Cancer Center Cary

Cary, United States

Duke Cancer Center - Investigational Chemotherapy Service

Durham, United States

Duke Cancer Center

Durham, United States

Duke University - Main Hospital and Clinics

Durham, United States

Duke Cancer Center Raleigh

Raleigh, United States

Virginia Mason Medical Center

Seattle, United States

Fred Hutchinson Cancer Center

Seattle, United States

University of Washington Medical Center- Montlake

Seattle, United States

Aichi Cancer Center

Nagoya, Japan

National Cancer Center Hospital East

Kashiwa, Japan

Kindai University Hospital- Osaka Medical Campus

Sakai, Japan

National Hospital Organization Kyushu Cancer Center

Fukuoka, Japan

Pan American Center for Oncology Trials, LLC - Dorado Office

Dorado, Puerto Rico

Pan American Center for Oncology Trials, LLC - Mayaguez Office

Mayagüez, Puerto Rico

Pan American Center for Oncology Trials, LLC - Ponce Office

Ponce, Puerto Rico

Pan American Center for Oncology Trials, LLC

San Juan, Puerto Rico

Taichung Veterans General Hospital

Taichung, Taiwan

National Cheng Kung University Hospital

Tainan, Taiwan

National Taiwan University Hospital

Taipei, Taiwan

Taipei Veterans General Hospital

Taipei, Taiwan

Trial contact

Contact information from ClinicalTrials.gov. Contact in English.

Share this trial

Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/7/2026.

You can help another person

We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.